Essential hypertension is a multifactorial disorder and is the main risk factor for renal and cardiovascular complications. The research on the genetics of hypertension has been frustrated by the small predictive value of the discovered genetic variants. The HYPERGENES Project investigated associations between genetic variants and essential hypertension pursuing a 2-stage study by recruiting cases and controls from extensively characterized cohorts recruited over many years in different European regions. The discovery phase consisted of 1865 cases and 1750 controls genotyped with 1M Illumina array. Best hits were followed up in a validation panel of 1385 cases and 1246 controls that were genotyped with a custom array of 14 055 markers. We identified a new hypertension susceptibility locus (rs3918226) in the promoter region of the endothelial NO synthase gene (odds ratio: 1.54 [95% CI: 1.37-1.73]; combined P=2.58 · 10(-13)). A meta-analysis, using other in silico/de novo genotyping data for a total of 21 714 subjects, resulted in an overall odds ratio of 1.34 (95% CI: 1.25-1.44; P=1.032 · 10(-14)). The quantitative analysis on a population-based sample revealed an effect size of 1.91 (95% CI: 0.16-3.66) for systolic and 1.40 (95% CI: 0.25-2.55) for diastolic blood pressure. We identified in silico a potential binding site for ETS transcription factors directly next to rs3918226, suggesting a potential modulation of endothelial NO synthase expression. Biological evidence links endothelial NO synthase with hypertension, because it is a critical mediator of cardiovascular homeostasis and blood pressure control via vascular tone regulation. This finding supports the hypothesis that there may be a causal genetic variation at this locus.

Genomewide association study using a high-density single nucleotide polymorphism array and case-control design identifies a novel essential hypertension susceptibility locus in the promoter region of endothelial NO synthase / E. Salvi, Z. Kutalik, N. Glorioso, P. Benaglio, F. Frau, T. Kuznetsova, H. Arima, C. Hoggart, J. Tichet, Y. P. Nikitin, C. Conti, J. Seidlerova, V. Tikhonoff, K. Stolarz-Skrzypek, T. Johnson, N. Devos, L. Zagato, S. Guarrera, R. Zaninello, A. Calabria, B. Stancanelli, C. Troffa, L. Thijs, F. Rizzi, G. Simonova, S. Lupoli, G. Argiolas, D. Braga, M. C. D'Alessio, M. F. Ortu, F. Ricceri, M. Mercurio, P. Descombes, M. Marconi, J. Chalmers, S. Harrap, J. Filipovsky, M. Bochud, L. Iacoviello, J. Ellis, A. V. Stanton, M. Laan, S. Padmanabhan, A. F. Dominiczak, N. J. Samani, O. Melander, X. Jeunemaitre, P. Manunta, A. Shabo, P. Vineis, F. P. Cappuccio, M. J. Caulfield, G. Matullo, C. Rivolta, P. B. Munroe, C. Barlassina, J. A. Staessen, J. S. Beckmann, D. Cusi. - In: HYPERTENSION. - ISSN 0194-911X. - 59:2(2012 Feb), pp. 248-255. [10.1161/HYPERTENSIONAHA.111.181990]

Genomewide association study using a high-density single nucleotide polymorphism array and case-control design identifies a novel essential hypertension susceptibility locus in the promoter region of endothelial NO synthase

E. Salvi;F. Frau;C. Conti;A. Calabria;F. Rizzi;S. Lupoli;D. Braga;C. Barlassina;D. Cusi
2012-02

Abstract

Essential hypertension is a multifactorial disorder and is the main risk factor for renal and cardiovascular complications. The research on the genetics of hypertension has been frustrated by the small predictive value of the discovered genetic variants. The HYPERGENES Project investigated associations between genetic variants and essential hypertension pursuing a 2-stage study by recruiting cases and controls from extensively characterized cohorts recruited over many years in different European regions. The discovery phase consisted of 1865 cases and 1750 controls genotyped with 1M Illumina array. Best hits were followed up in a validation panel of 1385 cases and 1246 controls that were genotyped with a custom array of 14 055 markers. We identified a new hypertension susceptibility locus (rs3918226) in the promoter region of the endothelial NO synthase gene (odds ratio: 1.54 [95% CI: 1.37-1.73]; combined P=2.58 · 10(-13)). A meta-analysis, using other in silico/de novo genotyping data for a total of 21 714 subjects, resulted in an overall odds ratio of 1.34 (95% CI: 1.25-1.44; P=1.032 · 10(-14)). The quantitative analysis on a population-based sample revealed an effect size of 1.91 (95% CI: 0.16-3.66) for systolic and 1.40 (95% CI: 0.25-2.55) for diastolic blood pressure. We identified in silico a potential binding site for ETS transcription factors directly next to rs3918226, suggesting a potential modulation of endothelial NO synthase expression. Biological evidence links endothelial NO synthase with hypertension, because it is a critical mediator of cardiovascular homeostasis and blood pressure control via vascular tone regulation. This finding supports the hypothesis that there may be a causal genetic variation at this locus.
Essential hypertension; Genetic epidemiology; Genetics association studies; NO; Risk factors; Adult; Case-Control Studies; Cohort Studies; Europe; Female; Genetic Predisposition to Disease; Genome-Wide Association Study; Genotype; Humans; Hypertension; Logistic Models; Male; Middle Aged; Nitric Oxide Synthase Type III; Polymorphism, Single Nucleotide; Predictive Value of Tests; Promoter Regions, Genetic; Internal Medicine
Settore MED/14 - Nefrologia
Settore MED/03 - Genetica Medica
Article (author)
File in questo prodotto:
File Dimensione Formato  
248.full.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 213.18 kB
Formato Adobe PDF
213.18 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/250121
Citazioni
  • ???jsp.display-item.citation.pmc??? 56
  • Scopus 114
  • ???jsp.display-item.citation.isi??? 112
social impact